Sutro Biopharma announces 1-for-10 reverse stock split effective Dec 3 to regain Nasdaq compliance

SUTRO BIOPHARMA, INC.

Reverse stock split at 1-for-10, effective 12:01 a.m. ET on December 3, 2025.
Outstanding shares reduced from ~85.2M to ~8.52M; symbol STRO unchanged, new CUSIP 869367201.
Intended to regain Nasdaq minimum bid price compliance; approved by stockholders on June 6, 2025.
No fractional shares issued; any fractional interest rounded up to nearest whole share.
Proportionate adjustments to equity awards, exercise prices, and shares reserved under equity plans.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

SUTRO BIOPHARMA, INC.: Amendment to Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-03).

Change: charter amendment
Effective: 2025-12-03

Exact text from the filing

On December 2, 2025, Sutro Biopharma, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Amendment ”) to its Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware to implement a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) to be effective as of 12:01 am Eastern time on December 3, 2025 (the “ Effective Time ”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-306786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.